BEYONDSPRING INC.

(BYSI)
  Bericht
Realtime-Estimate Cboe BZX  -  20:53 08.08.2022
1.445 USD   -4.30%
13.06.BeyondSpring Inc. gibt den Rücktritt von Führungskräften mit Wirkung zum 9. Juni 2022 bekannt
CI
09.06.BeyondSpring Inc. gibt den Rücktritt von Gordon L. Schooley als Chief Regulatory Officer bekannt
CI
22.04.BeyondSpring Finanzvorstand Elizabeth Czerepak tritt zurück
MT
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über BEYONDSPRING INC.
2018BeyondSpring to Present at the 10th Annual Biotech Showcase
2018BeyondSpring Appoints Life Sciences Veteran Patrick Fabbio to Board of Directors as an ..
2018Beyondspring Inc. Announces Board Changes
2017TRANSCRIPT : BeyondSpring Inc. - Shareholder/Analyst Call
2017BeyondSpring Inc. Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study ..
2017BeyondSpring's Lead Asset, Plinabulin, Recognized as 2017 National Science and Technolo..
2017BeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Preventi..
2017BeyondSpring Inc. Initiates Global Phase 2/3 Trial with Plinabulin in China for the Pre..
2017TRANSCRIPT : BeyondSpring Inc., Q3 2017 Earnings Call, Nov 09, 2017
2017BeyondSpring Reports Third Quarter 2017 Operational and Financial Results
2017BeyondSpring Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter..
2017BeyondSpring to Host Quarterly Operational Update Conference Call on November 9, 2017
2017BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Tria..
2017BeyondSpring Inc. Announces the First Patient Enrolled in China in Its Global Phase 2/3..
2017BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline
2017BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18..
2017BeyondSpring to Present at the 19th Annual Rodman & Renshaw Global Investment Conferenc..
2017Certain Ordinary Shares of BeyondSpring Inc. are subject to a Lock-Up Agreement Ending ..
2017TRANSCRIPT : BeyondSpring Inc., Q2 2017 Earnings Call, Aug 21, 2017
2017BeyondSpring Provides Operational Update for Second Quarter of 2017
2017BeyondSpring Inc. Reports Unaudited Consolidated Earnings Results for the Six Months En..
2017BeyondSpring to Present at the 2017 Southern California Investor Conference
2017BeyondSpring to Host Quarterly Operational Update Conference Call on August 21, 2017
2017China FDA Approves CTAs for BeyondSpring's Second Global Plinabulin Registrational Tria..
2017Beyondspring Inc. Announces China FDA Approves CTAs for Beyondspring’S Second Global P..
2017BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin a..
2017BeyondSpring to Present at the Jefferies 2017 Healthcare Conference
2017BeyondSpring to Attend Jefferies 2017 Healthcare Conference
2017BeyondSpring Inc. Announces Unaudited Consolidated Earnings Results for the First Quart..
2017BeyondSpring Reports First Quarter 2017 Financial Results
2017BeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences i..
2017BeyondSpring Files Its 2016 Annual Report on Form 20-F
2017TRANSCRIPT : BeyondSpring Inc., Q1 2017 Earnings Call, Apr 28, 2017
2017BeyondSpring Provides Quarterly Operational Update and Full Year 2016 Results
2017BeyondSpring Inc. Announces Consolidated Financial Results for the Year Ended December ..
2017BeyondSpring to Participate in Joseph Gunnar's Pioneers 2017 Conference on May 2 in New..
2017BeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for N..
2017BeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for N..
2017BeyondSpring to Host Quarterly Operational Update Conference Call on April 28, 2017
2017BeyondSpring Chief Medical Offer to Present on Lead Asset Plinabulin for Chemotherapy-I..
2017BeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presenta..
2017BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin f..
2017BeyondSpring Inc. Announces Clinical Trial Data for Plinabulin
2017BeyondSpring Inc. announced that it has received CAD 50.82096 million in funding
2017BEYONDSPRING INC.(NASDAQCM : BYSI) added to NASDAQ Composite Index
2017BeyondSpring Inc. announced that it expects to receive CAD 50.82 million in funding
2017BeyondSpring Inc. has completed an IPO in the amount of $3.48572 million.
2016BeyondSpring Inc. has filed an IPO in the amount of $100 million.
2016BeyondSpring Inc. announced that it has received $15.249999 million in funding from Epi..
Zur.1  2  3  4  5   6